Selank is a synthetic tuftsin-derived heptapeptide studied in neurotransmission models and a small anxiety trial, with its direct molecular targets and wider clinical effects still uncertain.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Tuftsin-derived regulatory peptide
Selank extends the four-residue tuftsin sequence with a Pro-Gly-Pro segment, producing the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its relationship to an endogenous immune-associated peptide provides a structural origin, not proof that it reproduces all tuftsin functions. Published work examines a defined experimental peptide and particular formulations, rather than establishing equivalence with an independently supplied research material.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
GABA-associated signaling is a proposed component of Selank activity. Rat gene-expression patterns overlapped with some responses to GABA, but such correlations do not demonstrate direct binding to a particular receptor. A human neuroblastoma cell experiment further showed that Selank alone did not change the measured transcription panel, emphasizing dependence on experimental context.
A rat frontal-cortex study measured a panel of genes involved in neurotransmission after Selank exposure. Changes varied with sampling time and overlapped partly with GABA-associated responses. These molecular observations support further pathway investigation rather than a complete receptor-level mechanism. [1]
In IMR-32 cells, Selank altered transcriptional responses when combined with GABA or olanzapine, although it did not independently change the measured genes. Combination effects cannot identify which molecular interaction is responsible or predict clinical combinations. [2]
A small randomized study compared Selank with medazepam in 62 patients with generalized anxiety or neurasthenia and reported improvements on clinical scales. The active-comparator design and limited reporting constrain interpretation beyond that study population. [3]
Study topics describe the cited models, not established benefits of this catalog material.
Human research provides an initial clinical signal, while the selected mechanistic studies chiefly measure transcription in rats or cultured cells. These endpoints cannot independently establish sustained anxiety treatment effects, cognitive enhancement, or a uniform response across neurological conditions.
The cited evidence does not resolve a single direct target, comprehensive pharmacology, or long-term clinical outcomes. Results obtained with study-specific preparations should not be assigned to WYZ material without independent identity and experimental comparability data.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Rat cortex transcription study; GABA-system modulation is an interpretation, not direct receptor-binding proof.
Selank alone did not change the measured gene panel; combination responses were context dependent.
Small Russian-language active-comparator trial involving 62 participants; broader clinical claims require additional evidence.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
